• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

ViaCyte

edit

ViaCyte is a preclinical therapeutic company focused on diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrates that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.

Recent Milestones

edit

• 
  ViaCyte — ViaCyte Receives $10.1 Million Strategic Partnership Award from CIRM to Continue Development of Diabetes Therapy (10/26/12)
  Posted 2/10/13 at 9:16pm via viacyte.com
• 
  ViaCyte added Paul Laikind as President and Chief Executive Officer.
  Posted 6/18/12 at 2:16am
• 
  ViaCyte added Allan Robins as Senior Vice President, Science & Technology.
  Posted 2/10/13 at 9:17pm

Videos

Screenshots

edit

Above: ViaCyte
Uploaded: 6/18/12

Sources

ViaCyte Receives $10.1 Million Strategic Partnership Award from CIRM to Continue Development of Diabetes Therapy (viacyte.com) [edit]